Gastrointestinal leukocytoclastic vasculitis: An adverse effect of sirolimus

Pediatric Transplantation

Volumn 9, Issue 1, 2005, Pages 97-100

  Nagarajan, Suja ^a   Friedrich, Tara ^a   Garcia, Manuel ^a   Kambham, Neeraja ^b   Sarwal, Minnie M ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effect; Gastrointestinal; Leukocytoclastic vasculitis; Sirolimus; Transplantation

Indexed keywords

FAMOTIDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; RAPAMYCIN; SUCRALFATE; TACROLIMUS;

ABDOMINAL PAIN; ADULT; ARTICLE; CADAVER KIDNEY; CASE REPORT; CHRONIC GLOMERULONEPHRITIS; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM INJURY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DUODENUM DISEASE; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTRITIS; HUMAN; KIDNEY FAILURE; LEUKOCYTOCLASTIC VASCULITIS; LEUKOPENIA; MELENA; ORGAN TRANSPLANTATION; STOMACH BIOPSY; VOMITING;

ABDOMINAL PAIN; ADULT; BIOPSY; CADAVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS; VASCULITIS, HYPERSENSITIVITY;

EID: 13744262355     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00245.x     Document Type: Article

References (15)

1. ABRAHM RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998: 10: 330-336.
2. FLECHNER SM. Minimizing calcineurin inhibitor drugs in renal transplantation. Transplant Proc 2003: 35(Suppl.): S118-S121.
3. OLYAEI AJ, DE MATTOS AM, BENNETT WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crt Care 2001: 7: 384-389.
4. SARWAL MM, VIDHUN JR, ALEXANDER SR, SATTERWHITE T, MILLAN M, SALVATIERRA O. Continued superior outcomes with modification and continued follow up of a steroid avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003: 76: 1331-1339.
5. SCHWARTZ GJ, HAYCOCK GB, EDELMAN CM JR, SPITZER A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976: 58: 259-263.
6. Wyeth Laboratories. Package Insert Sirolimus. Wyeth Laboratories, 2001.
7. TROPPMAN C, PIERCE JL, GANDHI MM, GALLAY BJ, MCVICAR JP, PEREZ RV. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 2003: 76: 426-429.
8. GUILBEAU JM. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002: 36: 1391-1395.
9. KAHAN BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. The Rapamune US Study Group. Lancet 2000: 356: 194-202.
10. MACDONALD AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001: 71: 271-280.
11. HARDINGER KL, CORNELIUS LA, TRULOCK EP, BRENNAN DC. Sirolimus-induced leucocytoclastic vasculitis. Transplantation 2002: 74: 739-743.
12. HOLDER SM, JOY MS, FALK RJ. Cutaneous and systemic manifestations of drug induced vasculitis. Ann Pharmacother 2002: 36: 130-147.
13. SAMS WM JR. Hypersensitivity angitis. J Inves Dermatol 1989: 93 (Suppl.): 78S-81S.
14. CROWSON AN, MIHM MC, MAGRO CM. Cutaneous vasculitis: a review. J Cutan Pathol 2003: 30: 161-173.
15. CROWE A, BRUELISAUER A, DUERR L, GUNTZ P, LEMAIR M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999: 27: 627-632.